Pridopidine clinical trials
Pridopidine is named as an intervention in 3 current clinical trials in our UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Canada, Israel, Ireland, Sweden, Czechia and Portugal registers. 2 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Prilenia (2). The most-studied condition is Amyotrophic Lateral Sclerosis. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
Where Pridopidine is approved
All regulators →- 1 EU orphan designation, most recently for treatment of amyotrophic lateral sclerosis (19 Jul 2021, positive)
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
How Pridopidine works
All drug targets →- Dopamine D2 receptor modulator ModulatorTarget: DRD2 dopamine receptor D2ChEMBL only
- Huntington diseasePhase 3
- Amyotrophic lateral sclerosisPhase 3
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL596802, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 13833, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Pridopidine
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Pridopidine
- ChEMBL
- CHEMBL596802
- DrugBank
- DB11947
- PubChem CID
- 9795739
- CAS number
- 346688-38-8
- FDA UNII
- HD4TW8S2VK
- Wikidata
- Q7242858
- Wikipedia
- Pridopidine
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Pridopidine
3 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
NCT07322003 · Amyotrophic Lateral Sclerosis
|
Phase 3 | Recruiting | Prilenia | Ireland, UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Poland, Canada, Israel |
|
Pridopidine Phase 3 Study in Huntington's Disease
NCT07609108 · Huntington Disease
|
Phase 3 | Recruiting | Prilenia | UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Czechia, Portugal, Canada |
|
HEALEY ALS Platform Trial - Master Protocol
NCT04297683 · ClinicalTrials.gov ↗ · Amyotrophic Lateral Sclerosis
|
Phase 2/3 | Active, closed | Merit E. Cudkowicz, MD | Israel |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Pridopidine in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Pridopidine. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants with Huntington’s disease (HD).
2026-526093-16-00 · CTIS ↗ · Nervous System Diseases
|
Phase 3 | Ongoing | Ferrer Internacional S.A., Prilenia Therapeutics B.V | Spain, Italy, Portugal + 6 more |
Conditions studied with Pridopidine
2 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Prilenia | 2 |
| Merit E. Cudkowicz, MD | 1 |
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Pridopidine trials
How many clinical trials are testing Pridopidine?
3 current trials in our UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Canada, Israel, Ireland, Sweden, Czechia and Portugal registers name Pridopidine as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Pridopidine trials recruiting patients?
Yes. 2 of the 3 trials are recruiting: 2 with sites in UK, 2 with sites in USA, 2 with sites in Germany, 2 with sites in France, 2 with sites in Spain, 2 with sites in Italy, 2 with sites in Netherlands, 2 with sites in Belgium, 2 with sites in Poland, 2 with sites in Canada, 1 with sites in Israel, 1 with sites in Ireland, 1 with sites in Sweden, 1 with sites in Czechia and 1 with sites in Portugal. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Pridopidine clinical trials?
Prilenia (2) and Merit E. Cudkowicz, MD (1). The number in brackets is how many trials each organisation leads.
Are there Pridopidine clinical trials in Ireland?
Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Pridopidine works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Pridopidine works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Pridopidine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.